34 related articles for article (PubMed ID: 7910021)
1. Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.
Chen J; Li G; Qin P; Chen J; Ye N; Waddington JL; Zhen X
Schizophr Bull; 2022 Mar; 48(2):474-484. PubMed ID: 34865170
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.
Sałaciak K; Pytka K
Neurosci Biobehav Rev; 2022 Jan; 132():1114-1136. PubMed ID: 34736882
[TBL] [Abstract][Full Text] [Related]
3. The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.
Sambo DO; Lebowitz JJ; Khoshbouei H
Pharmacol Ther; 2018 Jun; 186():152-167. PubMed ID: 29360540
[TBL] [Abstract][Full Text] [Related]
4. Sigma receptors [σRs]: biology in normal and diseased states.
Rousseaux CG; Greene SF
J Recept Signal Transduct Res; 2016 Aug; 36(4):327-388. PubMed ID: 26056947
[TBL] [Abstract][Full Text] [Related]
5. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.
Hayashi T; Tsai SY; Mori T; Fujimoto M; Su TP
Expert Opin Ther Targets; 2011 May; 15(5):557-77. PubMed ID: 21375464
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and therapeutic potential of sigma(1) receptor ligands.
Cobos EJ; Entrena JM; Nieto FR; Cendán CM; Del Pozo E
Curr Neuropharmacol; 2008 Dec; 6(4):344-66. PubMed ID: 19587856
[TBL] [Abstract][Full Text] [Related]
7. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Paquette MA; Foley K; Brudney EG; Meshul CK; Johnson SW; Berger SP
Psychopharmacology (Berl); 2009 Jul; 204(4):743-54. PubMed ID: 19283364
[TBL] [Abstract][Full Text] [Related]
8. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Paquette MA; Brudney EG; Putterman DB; Meshul CK; Johnson SW; Berger SP
Neuroreport; 2008 Jan; 19(1):111-5. PubMed ID: 18281903
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice.
Kim HW; Kwon YB; Roh DH; Yoon SY; Han HJ; Kim KW; Beitz AJ; Lee JH
Br J Pharmacol; 2006 Jun; 148(4):490-8. PubMed ID: 16682960
[TBL] [Abstract][Full Text] [Related]
10. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?
Davies MA; Compton-Toth BA; Hufeisen SJ; Meltzer HY; Roth BL
Psychopharmacology (Berl); 2005 Apr; 178(4):451-60. PubMed ID: 15765260
[TBL] [Abstract][Full Text] [Related]
11. Sigma receptors: biology and therapeutic potential.
Guitart X; Codony X; Monroy X
Psychopharmacology (Berl); 2004 Jul; 174(3):301-19. PubMed ID: 15197533
[TBL] [Abstract][Full Text] [Related]
12. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.
Hayashi T; Su TP
CNS Drugs; 2004; 18(5):269-84. PubMed ID: 15089113
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.
McDonald LM; Moran PM; Vythelingum GN; Joseph MH; Stephenson JD; Gray JA
Psychopharmacology (Berl); 2003 Sep; 169(3-4):321-31. PubMed ID: 14530903
[TBL] [Abstract][Full Text] [Related]
14. BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.
Okumura K; Ujike H; Akiyama K; Kuroda S
J Neural Transm (Vienna); 1996; 103(10):1153-61. PubMed ID: 9013402
[TBL] [Abstract][Full Text] [Related]
15. Purification, molecular cloning, and expression of the mammalian sigma1-binding site.
Hanner M; Moebius FF; Flandorfer A; Knaus HG; Striessnig J; Kempner E; Glossmann H
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):8072-7. PubMed ID: 8755605
[TBL] [Abstract][Full Text] [Related]
16. Evidence for genetically mediated dysfunction of the central dopaminergic system in the stargazer rat.
Brock JW; Ashby CR
Psychopharmacology (Berl); 1996 Jan; 123(2):199-205. PubMed ID: 8741944
[TBL] [Abstract][Full Text] [Related]
17. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.
Gewirtz GR; Gorman JM; Volavka J; Macaluso J; Gribkoff G; Taylor DP; Borison R
Neuropsychopharmacology; 1994 Feb; 10(1):37-40. PubMed ID: 7910021
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
Huber MT; Gotthardt U; Schreiber W; Krieg JC
Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
[TBL] [Abstract][Full Text] [Related]
19. A role for sigma binding in the antipsychotic profile of BMY 14802?
Taylor DP; Eison MS; Moon SL; Schlemmer RF; Shukla UA; VanderMaelen CP; Yocca FD; Gallant DJ; Behling SH; Boissard CG
NIDA Res Monogr; 1993; 133():125-57. PubMed ID: 8232511
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
